Adage Capital Partners’s Atrium Therapeutics RNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$828K Hold
100,000
– – ﹤0.01% 937
2026
Q2
$1.34M Sell
100,000
-83,580
-46% -$1.09M ﹤0.01% 890
2026
Q1
$2.45M Buy
+183,580
New +$2.58M ﹤0.01% 826

Other funds holding RNA

Adage Capital Partners's RNA Position: Q3 2026 in Review

Adage Capital Partners held its Atrium Therapeutics (RNA) position steady in Q3 2026 at 100,000 shares worth $828K. The position accounts for ﹤0.01% of the portfolio, ranked #937.

Adage Capital Partners first reported a position in RNA in Q1 2026 and has held it in 3 quarters since. The position peaked at $2.45M in Q1 2026. 148 funds tracked by Wall St. Rank hold RNA as of Q3 2026.

  • Adage Capital Partners held 100,000 shares of Atrium Therapeutics worth $828K as of Q3 2026.
  • Adage Capital Partners left its Atrium Therapeutics share count unchanged in Q3 2026.
  • Atrium Therapeutics made up ﹤0.01% of Adage Capital Partners's portfolio in Q3 2026, its #937 holding.
  • Adage Capital Partners first reported a position in Atrium Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Adage Capital Partners's Atrium Therapeutics position peaked at $2.45M in Q1 2026.
  • 148 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q3 2026.

Based on Adage Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.